Article info

Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups

Authors

  1. Correspondence to Dr David Hsiehchen; gbtwnow{at}gmail.com
View Full Text

Citation

Hsiehchen D, Espinoza M, Valero C, et al
Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups

Publication history

  • Accepted November 1, 2021
  • First published November 18, 2021.
Online issue publication 
May 08, 2023
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.